Dr. Reddy's Laboratories Ltd has generally positive cash flows and an excellent current ratio of 2.58. Additionally, the ...

Mayur Maheshwari, CEO of UPSIDA, said the Bulk Drug Pharma Park would be important in reducing India's dependence on China ...

Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

The BSE Sensex on Friday fell by 113.65 pts to 81,328.39 in early trade tracking negative cues from Asian peers.

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

Investors eye several stocks as the Reserve Bank of India is expected to announce a rate cut, potentially boosting the market ...

Stocks including Bajaj Finserv, IREDA, Coal India, Dr Reddy's Labs, Praj Industries, JSW Energy, SpiceJet, Ashoka Buildcon ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

Fintel reports that on June 5, 2025, HSBC upgraded their outlook for Dr. Reddy's Laboratories Limited - Depositary Receipt () ...

Dr. Reddy's Laboratories Ltd marked a 5.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...